QMS Medical

Who are in the management team of QMS Medical?

As of January 2021, the management team of QMS Medical includes Mahesh Makhija (Chairperson & Managing Director), Diti Makhija (Non-Executive Director), Guddi Makhija (Whole-time Director), Gautam Khanna and Raju Bhatia (Non-Executive Independent Directors), and Deepali Malpani (Company Secretary & Compliance Officer).

As of January 2021, the management team of QMS Medical includes the following members:<BR><BR>1. Mahesh Makhija - Chairperson & Managing Director<BR>2. Diti Makhija - Non-Executive & Non-Independent Director<BR>3. Guddi Makhija - Whole-time Director<BR>4. Gautam Khanna - Non-Executive & Independent Director<BR>5. Raju Bhatia - Non-Executive & Independent Director<BR>6. Deepali Malpani - Company Secretary & Compliance Officer<BR><BR>These individuals play key roles in the governance and operations of the company.

When is the next results date for QMS Medical?

No Upcoming Board Meetings

Has QMS Medical declared dividend?

QMS Medical Allied Services Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 20, 2024. However, the company has experienced negative total returns over various periods, indicating financial challenges despite the dividend announcement.

QMS Medical Allied Services Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 20 Sep 2024<BR><BR>Dividend Yield: 0.58%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.57%, the dividend return was 0%, resulting in a total return of -22.57%.<BR><BR>Over the past year, the price return was -11.98%, the dividend return was 0.47%, leading to a total return of -11.51%.<BR><BR>For the 2-year period, the price return was -28.34%, the dividend return was 0.65%, which resulted in a total return of -27.69%.<BR><BR>In the 3-year period, there was no price return, no dividend return, and the total return remained at 0.0%.<BR><BR>For the 4-year period, there was also no price return, no dividend return, and the total return stayed at 0.0%.<BR><BR>In the 5-year period, there was no price return, no dividend return, and the total return was 0.0%.<BR><BR>Overall, while QMS Medical has declared a dividend, the total returns over various periods indicate negative performance, particularly in the short and medium term, suggesting challenges in the company's financial performance despite the dividend announcement.

Who are the peers of the QMS Medical?

QMS Medical's peers include Syngene Intl., Dr Lal Pathlabs, and Poly Medicure, among others. Their management risks vary from excellent to below average, with Choksi Laborator showing the highest 1-year return at 115.17%, while QMS Medical's return is 0.00%.

Peers: The peers of QMS Medical are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Take Solutions, Royal, Hemant Surgical, Choksi Laborator, and Jeevan Scienti.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Hemant Surgical, and the rest have Below Average or Average management risk. Growth is Excellent at Royal, Average at Indegene and Poly Medicure, while Below Average growth is seen at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Hemant Surgical, and the rest. Excellent capital structure is noted at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Royal, and Hemant Surgical, while Below Average capital structure is found at Take Solutions, Choksi Laborator, and Jeevan Scienti.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Choksi Laborator at 115.17%, while the lowest is Take Solutions at -57.48%. QMS Medical's 1-year return is 0.00%, which is significantly lower than both extremes. Additionally, several peers, including Take Solutions, Hemant Surgical, and Vijaya Diagnost., have negative six-month returns.

What is the technical trend for QMS Medical?

As of May 16, 2025, QMS Medical's technical trend is mildly bearish, with bearish daily moving averages and mixed signals from MACD and Dow Theory, despite a mildly bullish weekly MACD.

As of 16 May 2025, the technical trend for QMS Medical has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the daily moving averages are bearish. The Bollinger Bands and KST both show bearish signals on the weekly timeframe. The Dow Theory suggests a mildly bullish trend on the weekly, but the overall indicators lean towards a bearish sentiment. The OBV is mildly bearish on the weekly and monthly. Overall, the current technical stance is mildly bearish, with key indicators being the bearish moving averages and the mixed signals from MACD and Dow Theory.

What does QMS Medical do?

QMS Medical Allied Services Ltd markets and distributes a variety of medical products and devices. As of March 2025, it reported net sales of 446 Cr and a net profit of 33 Cr, with a market cap of INR 148 Cr.

Overview: <BR>QMS Medical Allied Services Ltd is engaged in the marketing, trading, and distribution of a wide range of medical products, surgical instruments, medical equipment, and medical devices within the healthcare services industry, categorized as a micro-cap company.<BR><BR>History: <BR>The company was incorporated as 'QMS Medical Allied Services Private Limited' in 2017 and changed its status to a public limited company on October 22, 2020. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 446 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 33 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 148 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Industry P/E: 53 <BR>Dividend Yield: 0.60% <BR>Debt-Equity: 0.83 <BR>Return on Equity: 12.49% <BR>Price to Book: 1.77 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the QMS Medical?

The top shareholders of QMS Medical include Mahesh Pahalraj Makhija with 71.98%, individual investors with 22.95%, and a foreign institutional investor holding 0.01%. There are no mutual funds invested, and no pledged promoter holdings indicate strong promoter commitment.

The top shareholders of QMS Medical primarily include the promoters, with Mahesh Pahalraj Makhija holding the largest share at 71.98%. Additionally, individual investors collectively hold 22.95% of the shares. There is one foreign institutional investor (FII) that holds a small portion of 0.01%, but there are no mutual funds currently invested in the company. There are no pledged promoter holdings, indicating a strong commitment from the promoters.

How big is QMS Medical?

As of 24th July, QMS Medical Allied Services Ltd has a market capitalization of 143.00 Cr, with recent net sales of 157.94 Cr and a net profit of 11.24 Cr. The company has shareholder's funds of 78.51 Cr and total assets of 135.32 Cr.

As of 24th July, QMS Medical Allied Services Ltd has a market capitalization of 143.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, QMS Medical reported Net Sales of 157.94 Cr and a Net Profit of 11.24 Cr.<BR><BR>As of the latest annual period, the company has Shareholder's Funds amounting to 78.51 Cr and Total Assets of 135.32 Cr.

Is QMS Medical overvalued or undervalued?

As of August 14, 2025, QMS Medical is considered an attractive investment due to its undervalued status with a PE ratio of 12.50, an EV to EBITDA ratio of 8.20, and a PEG ratio of 0.63, especially when compared to higher valuations of peers like Poly Medicure and Blue Jet Health, despite a year-to-date stock decline of 33.85% against the Sensex's gain of 4.17%.

As of 14 August 2025, QMS Medical's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as undervalued, with a price-to-earnings (PE) ratio of 12.50, an EV to EBITDA ratio of 8.20, and a PEG ratio of 0.63, suggesting that it is trading at a discount relative to its earnings growth potential.<BR><BR>In comparison to its peers, QMS Medical stands out as more reasonably priced. For example, Poly Medicure has a PE ratio of 53.86, while Blue Jet Health is at 38.33, both of which are significantly higher than QMS Medical's valuation. Additionally, the company's return on capital employed (ROCE) is 13.06%, which further supports its attractiveness in the healthcare services industry. Despite recent stock performance lagging behind the Sensex, with a year-to-date decline of 33.85% compared to the Sensex's gain of 4.17%, the underlying valuation metrics suggest that QMS Medical presents a compelling investment opportunity.

How has been the historical performance of QMS Medical?

QMS Medical experienced significant growth from March 2024 to March 2025, with net sales rising to 156.01 Cr and profit after tax increasing to 13.70 Cr. The company also saw improvements in operating profit and cash flow from operating activities, despite a decline in cash flow from investing activities.

Answer:<BR>The historical performance of QMS Medical shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, QMS Medical reported net sales of 156.01 Cr, an increase from 122.13 Cr in the previous year. Total operating income also rose to 156.01 Cr from 122.13 Cr, while total expenditure increased to 130.60 Cr from 103.78 Cr. The operating profit (PBDIT) excluding other income improved to 25.41 Cr from 18.35 Cr, leading to an overall operating profit of 27.13 Cr compared to 18.81 Cr in the prior year. Profit before tax saw a rise to 18.66 Cr from 12.24 Cr, and profit after tax increased to 13.70 Cr from 9.00 Cr. The earnings per share (EPS) grew to 6.7 from 5.04. On the balance sheet, total assets increased to 189.79 Cr from 135.32 Cr, with total liabilities also rising to 189.79 Cr from 135.32 Cr. Cash flow from operating activities significantly improved to 20.00 Cr from 1.00 Cr, while cash flow from investing activities worsened to -45.00 Cr from -2.00 Cr. Overall, QMS Medical demonstrated a positive trend in revenue and profitability, alongside a notable increase in total assets and liabilities.

Should I buy, sell or hold QMS Medical Allied Services Ltd?

Which are the latest news on QMS Medical?

Why is QMS Medical Allied Services Ltd falling/rising?

As of 10-Apr, QMS Medical Allied Services Ltd is facing a decline in stock price to 78.50, down 1.88%. This decline is due to significant underperformance against its sector, decreased investor participation, and financial challenges, including a high Debt to EBITDA ratio and poor growth metrics.

As of 10-Apr, QMS Medical Allied Services Ltd is experiencing a decline in its stock price, currently at 78.50, which reflects a change of -1.5 or -1.88%. This downward movement can be attributed to several factors highlighted in the provided data. <BR><BR>Firstly, the stock has shown a significant underperformance against its sector, with a performance today that is -4.08% lower than the sector average. Additionally, the stock's delivery volume has drastically decreased by 86.49% compared to the 5-day average, indicating a falling investor participation which often correlates with declining interest in the stock.<BR><BR>Moreover, the stock's performance over various periods reveals a troubling trend. Over the past year, it has generated a return of -12.78%, significantly underperforming the benchmark Sensex, which has increased by 7.37% during the same timeframe. This consistent underperformance over the last three years, where the stock has failed to match the returns of the BSE500, further contributes to investor skepticism.<BR><BR>Financially, the company faces challenges with a high Debt to EBITDA ratio of 3.36 times, indicating a low ability to service its debt. This concern is compounded by poor long-term growth metrics, with net sales growing at an annual rate of only 13.26% and operating profit at 18.65% over the last five years. <BR><BR>While there has been an increase in institutional investor participation, with a 1.6% rise in their stake, the overall sentiment remains cautious due to the company's financial struggles and historical performance. Thus, the combination of poor stock performance, declining investor participation, and financial challenges are contributing to the falling stock price of QMS Medical Allied Services Ltd.